Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P53816

UPID:
PLAT3_HUMAN

ALTERNATIVE NAMES:
Adipose-specific phospholipase A2; Group XVI phospholipase A1/A2; H-rev 107 protein homolog; HRAS-like suppressor 1; HRAS-like suppressor 3; HREV107-3; Renal carcinoma antigen NY-REN-65

ALTERNATIVE UPACC:
P53816; B2R7Q4; B7XAK5; Q3SYI3; Q9HDD1

BACKGROUND:
The protein Phospholipase A and acyltransferase 3, also recognized as H-rev 107 protein homolog and HRAS-like suppressor, is integral to lipid modification and organelle degradation in lens transparency. It exhibits phospholipase A1/2 and acyltransferase activities, crucial for cellular lipid remodeling and signaling. Additionally, it acts as a host factor for picornaviruses, suggesting its role in viral infection processes.

THERAPEUTIC SIGNIFICANCE:
Exploring the multifunctional role of Phospholipase A and acyltransferase 3 offers a promising avenue for developing novel therapeutic interventions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.